Compare BABA & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BABA | JNJ |
|---|---|---|
| Founded | 1999 | 1886 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.4B | 542.4B |
| IPO Year | 2014 | 2003 |
| Metric | BABA | JNJ |
|---|---|---|
| Price | $99.76 | $263.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 41 | 23 |
| Target Price | $186.27 | ★ $279.41 |
| AVG Volume (30 Days) | 5.9M | ★ 6.6M |
| Earning Date | 11-24-2026 | 10-13-2026 |
| Dividend Yield | 1.03% | ★ 2.00% |
| EPS Growth | N/A | ★ 90.50 |
| EPS | N/A | ★ 4.49 |
| Revenue | N/A | N/A |
| Revenue This Year | $9.52 | $7.46 |
| Revenue Next Year | $12.63 | $6.60 |
| P/E Ratio | ★ $21.20 | $59.73 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $91.99 | $184.66 |
| 52 Week High | $182.50 | $281.07 |
| Indicator | BABA | JNJ |
|---|---|---|
| Relative Strength Index (RSI) | 30.91 | 53.03 |
| Support Level | $91.99 | $262.26 |
| Resistance Level | $121.13 | $266.91 |
| Average True Range (ATR) | 2.52 | 5.81 |
| MACD | -0.73 | 1.14 |
| Stochastic Oscillator | 2.11 | 76.08 |
Alibaba is the world's largest online and mobile commerce company as measured by gross merchandise volume. It operates China's online marketplaces, including Taobao (consumer-to-consumer) and Tmall (business-to-consumer). The China retail e-commerce platform is the most valuable cash flow-generating business at Alibaba. Additional revenue sources include China wholesale e-commerce, international retail and wholesale e-commerce, local consumer services, travel services, cloud computing, digital media and entertainment, Cainiao logistics services, and other businesses.
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.